ZURICH (Reuters) - The U.S. Food and Drug Administration has accepted Novartis unit Sandoz's regulatory submission for approval of a biosimilar copy of Amgen's blockbuster Enbrel drug, the Swiss ...
Alston & Bird allege their client has suffered more than $1 billion in lost sales from being unable to manufacture a biosimilar product in the United States to compete with Amgen's blockbuster Enbrel ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results